These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 20955636)
21. Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls. Young-Min SA; Beeton C; Laughton R; Plumpton T; Bartram S; Murphy G; Black C; Cawston TE Ann Rheum Dis; 2001 Sep; 60(9):846-51. PubMed ID: 11502611 [TBL] [Abstract][Full Text] [Related]
22. [Involvement of matrix metalloproteinases in the regulation of myocardial extracellular matrix in patients with congestive heart failure]. Yang YJ; Zhang X; Zhu WL; Huang Y Zhonghua Yi Xue Za Zhi; 2006 Jun; 86(24):1693-6. PubMed ID: 16854324 [TBL] [Abstract][Full Text] [Related]
23. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy. Rysz J; Banach M; Stolarek RA; Pasnik J; Cialkowska-Rysz A; Koktysz R; Piechota M; Baj Z J Nephrol; 2007; 20(4):444-52. PubMed ID: 17879211 [TBL] [Abstract][Full Text] [Related]
24. Increases in circulating matrix metalloproteinase-9 levels following fibrinolysis for acute pulmonary embolism. Mühl D; Ghosh S; Uzuelli JA; Lantos J; Tanus-Santos JE Thromb Res; 2010 Jun; 125(6):549-53. PubMed ID: 20307903 [TBL] [Abstract][Full Text] [Related]
25. Elevated matrix metalloproteinase expression after stent implantation is associated with restenosis. Ge J; Shen C; Liang C; Chen L; Qian J; Chen H Int J Cardiol; 2006 Sep; 112(1):85-90. PubMed ID: 16316696 [TBL] [Abstract][Full Text] [Related]
26. Significant increases in serum and plasma concentrations of matrix metalloproteinases 3 and 9 in patients with rapidly destructive osteoarthritis of the hip. Masuhara K; Nakai T; Yamaguchi K; Yamasaki S; Sasaguri Y Arthritis Rheum; 2002 Oct; 46(10):2625-31. PubMed ID: 12384920 [TBL] [Abstract][Full Text] [Related]
27. Circulating total and active metalloproteinase-9 and tissue inhibitor of metalloproteinases-1 in patients with systemic lupus erythomatosus. Robak E; Wierzbowska A; Chmiela M; Kulczycka L; Sysa-Jedrejowska A; Robak T Mediators Inflamm; 2006; 2006(1):17898. PubMed ID: 16864898 [TBL] [Abstract][Full Text] [Related]
28. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity. Chen CH; Lin KC; Yu DT; Yang C; Huang F; Chen HA; Liang TH; Liao HT; Tsai CY; Wei JC; Chou CT Rheumatology (Oxford); 2006 Apr; 45(4):414-20. PubMed ID: 16287916 [TBL] [Abstract][Full Text] [Related]
29. High serum TIMP-1 is associated with adverse prognosis in endometrial carcinoma. Honkavuori M; Talvensaari-Mattila A; Puistola U; Turpeenniemi-Hujanen T; Santala M Anticancer Res; 2008; 28(5A):2715-9. PubMed ID: 19035300 [TBL] [Abstract][Full Text] [Related]
30. Specific changes in plasma concentrations of matrix metalloproteinase-2 and -9, TIMP-1 and TGF-beta1 in patients with distinct types of primary glomerulonephritis. Bauvois B; Mothu N; Nguyen J; Nguyen-Khoa T; Nöel LH; Jungers P Nephrol Dial Transplant; 2007 Apr; 22(4):1115-22. PubMed ID: 17205957 [TBL] [Abstract][Full Text] [Related]
31. [Roles of matrix metalloproteinases, tissue inhibitor of matrix metalloproteinase and hs-CRP in Kawasaki disease]. Chen R; Zhang AR; Zhao XX; Li ZH Zhongguo Dang Dai Er Ke Za Zhi; 2009 Dec; 11(12):989-91. PubMed ID: 20113606 [TBL] [Abstract][Full Text] [Related]
32. Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours. Määtta M; Talvensaari-Mattila A; Turpeenniemi-Hujanen T; Santala M Anticancer Res; 2007; 27(4C):2753-8. PubMed ID: 17695443 [TBL] [Abstract][Full Text] [Related]
33. Effect of interferon beta-1a on serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in relapsing remitting multiple sclerosis patients. One year follow-up results. Karabudak R; Kurne A; Guc D; Sengelen M; Canpinar H; Kansu E J Neurol; 2004 Mar; 251(3):279-83. PubMed ID: 15015006 [TBL] [Abstract][Full Text] [Related]
34. Serum or plasma: what kind of blood sample should be used to measure circulating matrix metalloproteinases and their inhibitors? Jung K J Neuroimmunol; 2005 May; 162(1-2):1-2. PubMed ID: 15833353 [No Abstract] [Full Text] [Related]
35. Comparison of free radicals and antioxidant enzymes in chronic otitis media with and without tympanosclerosis. Karlidağ T; Ilhan N; Kaygusuz I; Keleş E; Yalçin S Laryngoscope; 2004 Jan; 114(1):85-9. PubMed ID: 14710000 [TBL] [Abstract][Full Text] [Related]
36. Variations with time of plasma concentrations of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2. Rossignol P; Jacob MP; Cambillau M; Mouradian D; Plouin PF; Chatellier G Thromb Res; 2007; 119(2):261-3. PubMed ID: 16530811 [No Abstract] [Full Text] [Related]
37. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in congestive heart failure. Gerlach RF; Tanus-Santos JE Am Heart J; 2006 Jul; 152(1):e9. PubMed ID: 16824824 [No Abstract] [Full Text] [Related]
38. Serum levels of matrix metalloproteinase-9 and its tissue inhibitor (TIMP-1) in acute disseminated encephalomyelitis. Ichiyama T; Kajimoto M; Suenaga N; Maeba S; Matsubara T; Furukawa S J Neuroimmunol; 2006 Mar; 172(1-2):182-6. PubMed ID: 16321449 [TBL] [Abstract][Full Text] [Related]
39. Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension. Tan J; Hua Q; Xing X; Wen J; Liu R; Yang Z Hypertens Res; 2007 Oct; 30(10):959-63. PubMed ID: 18049028 [TBL] [Abstract][Full Text] [Related]
40. Altered pattern of circulating matrix metalloproteinases -2,- 9 and tissue inhibitor of metalloproteinase-2 in patients with HCV-related chronic hepatitis. Relationship to histological features. Bruno CM; Valenti M; Bertino G; Ardiri A; Consolo M; Mazzarino CM; Amoroso A; Neri S Panminerva Med; 2009 Dec; 51(4):191-6. PubMed ID: 20195229 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]